• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: Chairman, President & CEO Harris Theodore L was granted 28,964 shares and covered exercise/tax liability with 11,442 shares, increasing direct ownership by 28% to 79,159 units (SEC Form 4)

    4/11/25 6:08:15 PM ET
    $BCPC
    Major Chemicals
    Industrials
    Get the next $BCPC alert in real time by email
    SEC FORM 4/A SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Harris Theodore L

    (Last) (First) (Middle)
    C/O BALCHEM CORPORATION
    5 PARAGON DRIVE

    (Street)
    MONTVALE NJ 07645

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    BALCHEM CORP [ BCPC ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chairman, President & CEO
    3. Date of Earliest Transaction (Month/Day/Year)
    02/12/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    02/14/2025
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 02/12/2025 A 6,600(1) A $0 68,237 D
    Common Stock 02/13/2025 A 22,364(2) A $0 90,601 D
    Common Stock 02/13/2025 F 11,442(3) D $163.14 79,159 D
    Common Stock 1,866 I 401(k) Plan
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option $159.18 02/12/2025 A 21,500 (4) 02/12/2035 Common Stock 21,500 $0 21,500 D
    Explanation of Responses:
    1. Ownership of restricted stock vests in Reporting Person ratably over a 3-year period (25% on the first anniversary of the grant date, 25% on the second anniversary of the grant date, and 50% on the third anniversary of the grant date), subject to restrictions on transfer in accordance with the provisions of a Restricted Stock Grant Agreement between the Issuer and the Reporting Person.
    2. Represents the vesting of performance stock units (includes 369 dividend equivalent shares) for the 2022-2024 performance period.
    3. 11,442 of 22,364 the performance stock units that vested on February 13, 2025 were withheld to cover tax requirement due upon vesting.
    4. Options vest 20% Year 1; 40% Year 2: and 40% Year 3.
    Remarks:
    This Form 4/A amends and restates the original Form 4 filed on February 14, 2025, which inadvertently noted the vesting period for restricted stock as 3 years from the grant date, instead of a ratable vesting over a 3-year period.
    /s/ Travis Larsen, Attorney in Fact for Theodore L Harris 04/11/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $BCPC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BCPC

    DatePrice TargetRatingAnalyst
    3/8/2022$170.00 → $155.00Buy
    HC Wainwright & Co.
    2/22/2022$175.00Neutral → Buy
    Sidoti
    1/10/2022$160.00 → $170.00Buy
    HC Wainwright & Co.
    11/29/2021$175.00Buy → Neutral
    Sidoti
    8/2/2021$140.00 → $145.00Overweight → Equal-Weight
    Stephens & Co.
    8/2/2021$145.00 → $160.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $BCPC
    Financials

    Live finance-specific insights

    See more
    • Balchem Corporation Reports First Quarter 2025 Financial Results

      MONTVALE, N.J., April 24, 2025 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ:BCPC) reported today financial results for its 2025 fiscal first quarter ended March 31, 2025. For the quarter, the Company reported net sales of $250.5 million, net earnings of $37.1 million, adjusted EBITDA(a) of $66.3 million, and free cash flow(a) of $31.0 million. Ted Harris, Chairman, President and CEO of Balchem said, "The first quarter was an excellent start to the year for Balchem, with sales and earnings growth in all three segments. We delivered record net sales and adjusted EBITDA, strong net earnings, and solid first quarter cash flows." First Quarter 2025 Financial Highlights: Record net sales o

      4/24/25 7:00:00 AM ET
      $BCPC
      Major Chemicals
      Industrials
    • Balchem Corporation Announces Quarterly Conference Call for First Quarter 2025 Financial Results on April 24, 2025

      MONTVALE, N.J., April 11, 2025 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ:BCPC) today announced that a conference call will be held on Thursday, April 24, 2025, at 11:00 AM Eastern Time (ET) to review first quarter 2025 results. Ted Harris, Chairman of the Board, President and CEO, and Martin Bengtsson, CFO, will host the call. First quarter results will be published prior to the market opening on Thursday, April 24, 2025. The press release, and its accompanying financial exhibits, will also be available on the Company website, www.balchem.com, prior to the conference call. We invite you to listen to the conference by calling toll-free 1-877-407-8289 (local dial-in 1-201-689-8341),

      4/11/25 7:00:00 AM ET
      $BCPC
      Major Chemicals
      Industrials
    • Balchem Corporation Reports Fourth Quarter and Full Year 2024 Financial Results

      MONTVALE, N.J., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ:BCPC) reported today financial results for its 2024 fiscal fourth quarter ended December 31, 2024. For the quarter, the Company reported net sales of $240.0 million, net earnings of $33.6 million, adjusted EBITDA(a) of $62.8 million, and free cash flow(a) of $39.8 million. Ted Harris, Chairman, President, and CEO of Balchem said, "The fourth quarter capped off another very strong year for Balchem. We delivered record fourth quarter net sales and adjusted EBITDA, with top and bottom line year over year growth in each of our three segments." Fourth Quarter 2024 Financial Highlights:

      2/21/25 7:00:00 AM ET
      $BCPC
      Major Chemicals
      Industrials

    $BCPC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Balchem Corporation to Present at the Wells Fargo Industrials and Materials Conference on June 11, 2025

      MONTVALE, N.J., May 28, 2025 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ:BCPC), a global specialty ingredient manufacturer for health and nutrition markets, announced they will present at the Wells Fargo Industrials and Materials Conference on June 11, 2025. Ted Harris, Chairman of the Board, Chief Executive Officer, and President, Martin Bengtsson, Chief Financial Officer, and Allison Baurichter, Senior Director Investor Relations will present at the conference. About Balchem Corporation Balchem Corporation develops, manufactures and markets specialty ingredients that improve and enhance the health and well-being of life on the planet, providing state-of-the-art solutions and the fi

      5/28/25 7:00:00 AM ET
      $BCPC
      Major Chemicals
      Industrials
    • Balchem Corporation to Participate in the dbAccess Global Consumer Conference on June 4, 2025

      MONTVALE, N.J., May 21, 2025 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ:BCPC), a global specialty ingredient manufacturer for health and nutrition markets, announced they will participate in the dbAccess Global Consumer Conference on June 4, 2025. Ted Harris, Chairman of the Board, Chief Executive Officer, and President and Martin Bengtsson, Chief Financial Officer will participate at the conference. About Balchem Corporation Balchem Corporation develops, manufactures and markets specialty ingredients that improve and enhance the health and well-being of life on the planet, providing state-of-the-art solutions and the finest quality products for a range of industries worldwide. The

      5/21/25 7:00:00 AM ET
      $BCPC
      Major Chemicals
      Industrials
    • Balchem Corporation Reports First Quarter 2025 Financial Results

      MONTVALE, N.J., April 24, 2025 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ:BCPC) reported today financial results for its 2025 fiscal first quarter ended March 31, 2025. For the quarter, the Company reported net sales of $250.5 million, net earnings of $37.1 million, adjusted EBITDA(a) of $66.3 million, and free cash flow(a) of $31.0 million. Ted Harris, Chairman, President and CEO of Balchem said, "The first quarter was an excellent start to the year for Balchem, with sales and earnings growth in all three segments. We delivered record net sales and adjusted EBITDA, strong net earnings, and solid first quarter cash flows." First Quarter 2025 Financial Highlights: Record net sales o

      4/24/25 7:00:00 AM ET
      $BCPC
      Major Chemicals
      Industrials

    $BCPC
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Balchem Corporation

      SCHEDULE 13G/A - BALCHEM CORP (0000009326) (Subject)

      5/14/25 4:34:20 PM ET
      $BCPC
      Major Chemicals
      Industrials
    • SEC Form DEFA14A filed by Balchem Corporation

      DEFA14A - BALCHEM CORP (0000009326) (Filer)

      4/25/25 4:17:40 PM ET
      $BCPC
      Major Chemicals
      Industrials
    • SEC Form DEF 14A filed by Balchem Corporation

      DEF 14A - BALCHEM CORP (0000009326) (Filer)

      4/25/25 4:15:49 PM ET
      $BCPC
      Major Chemicals
      Industrials

    $BCPC
    Leadership Updates

    Live Leadership Updates

    See more
    • AzurRx BioPharma Announces Appointment of Terry Coelho to its Board of Directors

      BOCA RATON, Fla., Aug. 16, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. ("AzurRx" or the "Company") (NASDAQ:AZRX), a company specializing in the development of targeted non-systemic, therapies for gastrointestinal (GI) diseases, today announced the appointment of Terry Coelho to its Board of Directors effective immediately. The appointment increases the size of AzurRx's Board to seven members. Ms. Coelho currently serves as the Executive Vice President and Chief Financial Officer at BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a commercial-stage specialty pharmaceutical company. During her more than 30-year career, Ms. Coelho has held numerous senior level financial an

      8/16/21 8:00:00 AM ET
      $AZRX
      $BCPC
      $BDSI
      Major Pharmaceuticals
      Health Care
      Major Chemicals
      Industrials

    $BCPC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. reiterated coverage on Balchem with a new price target

      HC Wainwright & Co. reiterated coverage of Balchem with a rating of Buy and set a new price target of $155.00 from $170.00 previously

      3/8/22 6:19:56 AM ET
      $BCPC
      Major Chemicals
      Industrials
    • Balchem upgraded by Sidoti with a new price target

      Sidoti upgraded Balchem from Neutral to Buy and set a new price target of $175.00

      2/22/22 8:56:13 AM ET
      $BCPC
      Major Chemicals
      Industrials
    • HC Wainwright & Co. reiterated coverage on Balchem with a new price target

      HC Wainwright & Co. reiterated coverage of Balchem with a rating of Buy and set a new price target of $170.00 from $160.00 previously

      1/10/22 6:15:56 AM ET
      $BCPC
      Major Chemicals
      Industrials

    $BCPC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Balchem Corporation

      SC 13G/A - BALCHEM CORP (0000009326) (Subject)

      11/13/24 6:56:07 PM ET
      $BCPC
      Major Chemicals
      Industrials
    • SEC Form SC 13G/A filed by Balchem Corporation (Amendment)

      SC 13G/A - BALCHEM CORP (0000009326) (Subject)

      2/13/24 4:59:02 PM ET
      $BCPC
      Major Chemicals
      Industrials
    • SEC Form SC 13G/A filed by Balchem Corporation (Amendment)

      SC 13G/A - BALCHEM CORP (0000009326) (Subject)

      2/9/24 11:29:17 AM ET
      $BCPC
      Major Chemicals
      Industrials

    $BCPC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: SVP and GM, Specialty Products Van Gunsteren Job Leonard was granted 2,128 shares and covered exercise/tax liability with 964 shares, increasing direct ownership by 14% to 9,446 units (SEC Form 4)

      4/A - BALCHEM CORP (0000009326) (Issuer)

      4/11/25 7:11:10 PM ET
      $BCPC
      Major Chemicals
      Industrials
    • Amendment: SVP & Chief HR Officer Tignor Michael Brent was granted 3,497 shares and covered exercise/tax liability with 1,156 shares, increasing direct ownership by 35% to 9,123 units (SEC Form 4)

      4/A - BALCHEM CORP (0000009326) (Issuer)

      4/11/25 6:43:35 PM ET
      $BCPC
      Major Chemicals
      Industrials
    • Amendment: SVP Chief Supply Chain Officer Reid Martin Luther was granted 3,889 shares and covered exercise/tax liability with 1,059 shares, increasing direct ownership by 49% to 8,591 units (SEC Form 4)

      4/A - BALCHEM CORP (0000009326) (Issuer)

      4/11/25 6:38:36 PM ET
      $BCPC
      Major Chemicals
      Industrials